AusperBio website screenshot

AusperBio

AusperBio — AusperBio Therapeutics, Inc. in the United States and Ausper Biopharma Co., Ltd. (杭州浩博医药有限公司) in Hangzhou, China — is a clinical-stage biopharmaceutical company founded in 2019 that develops oligonucleotide and targeted delivery technologies, with an initial focus on achieving a functional cure for chronic hepatitis B infection. Its proprietary Med-Oligo antisense oligonucleotide (ASO) platform pairs novel ASO design and optimization with targeted delivery conjugation chemistry, and its Au-HALO hepatocyte-targeting delivery technology extends the same modular approach to siRNA. The lead candidate AHB-137 is an unconjugated ASO that completed enrollment in two Phase II trials and received China CDE clearance to enter Phase III; a second clinical candidate, AHB-171, is a hepatocyte-targeted siRNA. The company has raised more than $200M across Series B, B+ and B2 rounds from investors including Qiming Venture Partners, HanKang Capital, CDH Investments, Sherpa Capital, YuanBio Venture Capital and Genesis Capital. AusperBio sells therapeutics, not software: it publishes no developer program, no public API, no SDK and no machine-readable API contract. Its only machine-readable surface is the private Spring Boot CMS backend that renders ausperbio.com, whose springdoc API description is correctly locked behind authentication.

AusperBio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Biopharmaceutical, and Life Sciences.

AusperBio’s developer surface includes engineering blog, product news, support, and 12 more developer resources.

12.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyPharmaceuticalsBiopharmaceuticalLife SciencesTherapeuticsOligonucleotideAntisense OligonucleotidesiRNAClinical TrialsHepatitis BDrug DevelopmentHealthChina

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 12.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 1.1 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.9 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ausperbio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Ausperbio Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

Access & Security 1

Authentication, authorization, and security posture

Operate 2

Status, limits, changes, and where to get help

Commercial 2

Pricing, plans, and the legal terms of use

Company 6

The organization behind the API

Other 3

Properties that don't map to a standard resource type

Source (apis.yml)

apis.yml Raw ↑
aid: ausperbio
name: AusperBio
description: 'AusperBio — AusperBio Therapeutics, Inc. in the United States and Ausper Biopharma Co., Ltd. (杭州浩博医药有限公司) in
  Hangzhou, China — is a clinical-stage biopharmaceutical company founded in 2019 that develops oligonucleotide and targeted
  delivery technologies, with an initial focus on achieving a functional cure for chronic hepatitis B infection. Its proprietary
  Med-Oligo antisense oligonucleotide (ASO) platform pairs novel ASO design and optimization with targeted delivery conjugation
  chemistry, and its Au-HALO hepatocyte-targeting delivery technology extends the same modular approach to siRNA. The lead
  candidate AHB-137 is an unconjugated ASO that completed enrollment in two Phase II trials and received China CDE clearance
  to enter Phase III; a second clinical candidate, AHB-171, is a hepatocyte-targeted siRNA. The company has raised more than
  $200M across Series B, B+ and B2 rounds from investors including Qiming Venture Partners, HanKang Capital, CDH Investments,
  Sherpa Capital, YuanBio Venture Capital and Genesis Capital. AusperBio sells therapeutics, not software: it publishes no
  developer program, no public API, no SDK and no machine-readable API contract. Its only machine-readable surface is the
  private Spring Boot CMS backend that renders ausperbio.com, whose springdoc API description is correctly locked behind authentication.'
image: https://www.ausperbio.com/favicon.ico
url: https://raw.githubusercontent.com/api-evangelist/ausperbio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: no-api-surface
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Biopharmaceutical
- Life Sciences
- Therapeutics
- Oligonucleotide
- Antisense Oligonucleotide
- siRNA
- Clinical Trials
- Hepatitis B
- Drug Development
- Health
- China
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/ausperbio-domain-security.yml
- type: Website
  url: https://www.ausperbio.com/
- type: About
  url: https://www.ausperbio.com/company.html
- type: Team
  url: https://www.ausperbio.com/leadership.html
- type: Product
  url: https://www.ausperbio.com/platform.html
  description: Med-Oligo ASO platform and Au-HALO targeted delivery technology.
- type: Research
  url: https://www.ausperbio.com/pipeline.html
  description: Clinical pipeline — AHB-137 (ASO) and AHB-171 (siRNA) for chronic hepatitis B.
- type: Blog
  url: https://www.ausperbio.com/news.html
- type: News
  url: https://www.ausperbio.com/news.html
- type: Support
  url: https://www.ausperbio.com/contact-us.html
- type: Contact
  url: https://www.ausperbio.com/contact-us.html
- type: Careers
  url: https://www.ausperbio.com/careers.html
- type: TermsOfService
  url: https://www.ausperbio.com/term.html
- type: PrivacyPolicy
  url: https://www.ausperbio.com/privacy.html
- type: LinkedIn
  url: https://www.linkedin.com/company/ausperbio
- type: LLMsTxt
  url: llms/ausperbio-llms.txt
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: AusperBio develops antisense-oligonucleotide and siRNA drugs for chronic hepatitis B, so there is no software product
    to expose; ausperbio.com is a Vue single-page app that returns an identical 2,601-byte shell (md5 519d85ce…) for every
    path including invented ones, and the only machine-readable API description on the estate is the springdoc description
    of the private Spring Boot CMS at cms.ausperbio.com/jzy-admin/, which is correctly 401-gated and is site infrastructure
    rather than a product surface.
  evidence:
  - url: https://www.ausperbio.com/openapi.json
    status: 200
    note: Soft 404 — byte-identical to the SPA shell returned for a nonexistent control path.
  - url: https://www.ausperbio.com/definitely-not-a-real-path-zzz999
    status: 200
    note: Control path proving every 200 on this host is the SPA catch-all.
  - url: https://www.ausperbio.com/llms.txt
    status: 200
    note: Soft 404 — SPA shell, not an llms.txt.
  - url: https://www.ausperbio.com/.well-known/agent-card.json
    status: 200
    note: Soft 404 — SPA shell, not an agent card. No A2A card published.
  - url: https://cms.ausperbio.com/jzy-admin/v3/api-docs
    status: 200
    note: Returns {"code":401,"msg":""} — springdoc API description exists but is authentication-gated.
  - url: https://cms.ausperbio.com/jzy-admin/doc.html
    status: 401
  - url: https://api.ausperbio.com/
    status: 0
    note: No such host in DNS. Same for developer. and docs. subdomains.
  checked: '2026-08-06'